@alison-tree.bsky.social @ccparker.bsky.social #prostatecancer #pcsm

Science News@scinews.bsky.social · last yr.

This review discusses the contemporary management of all stages of prostate cancer, enabling holistic individualization of treatment, and describes the promise of future research to further improve outcomes. Open Access acsjournals.onlinelibrary.wiley.com/doi/10.3322/...

Happy to share our review on hypo- and ultra-hypofractionation for prostate cancer radiotherapy, just published in Seminars in Radiation Oncology @alison-tree.bsky.social @harshanigreen.bsky.social Full-text link: authors.elsevier.com/a/1lFrI3lXQo...

Management of Testicular Cancer @ascocancer.bsky.social doi.org/10.1200/OP-2...

Excited to see the HERMES trial results in print www.sciencedirect.com/science/arti... Small trial but toxicity of 2 fractions looks promising at 24/27 Gy, no GI tox of G2 or higher out to 12 weeks @momentumstudy.bsky.social @icr.ac.uk

HERMES: Randomised trial of 2-fraction or 5-fraction MRI-guided adaptive prostate radiotherapy

To demonstrate safety and feasibility of 2-fraction stereotactic body radiotherapy (SBRT) for prostate cancer.This single centre, non-comparative, pha…

sciencedirect.com